Regeneron Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Regeneron Pharmaceuticals Inc in the second quarter 2026?
Regeneron Pharmaceuticals Inc achieved a return on average equity (ROE) of 13.81 % in its second quarter 2026, which is below Regeneron Pharmaceuticals Inc 's average return on equity, which stands at 22.32%.

ROE fell compared to the first quarter 2026, despite the net income growth of 78.34% from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 44 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 988 to 991.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	5.92 %	6.93 %	6.48 %	5.56 %	-
Y / Y Net Income Change	-6.81 %	-10.08 %	-7.97 %	8.91 %	-2.84 %
Net Income (TTM) in Millions	4,329	4,423	4,505	4,578	4,459
Return On Equity (TTM)	13.81 %	14.32 %	14.83 %	15.31 %	15.11 %
REGN's Total Ranking	# 991	# 988	# 807	# 811	# 770
Equity (TTM) in Millions	31,711	31,424	31,257	30,958	29,939
Seq. Equity Change	0.92 %	0.53 %	0.97 %	3.4 %	1.88 %
Seq. Net Income Change	78.34 %	-13.9 %	-42.15 %	4.92 %	72.08 %

Back to REGN Management Effectiveness >> REGN's 5 Years Annual ROE >> Compare REGN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 45
Sector	# 115
Overall	# 991

Return On Equity Statistics
High	Average	Low
95.27 %	22.32 %	-46.44 %
(Dec 31 2012)		(Dec 31 2011)

REGN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	31,257	29,354	25,973	22,664	18,769
Y / Y Equity Change	6.48 %	13.02 %	14.6 %	20.75 %	70.23 %
Net Income in Millions	4,505	4,413	3,954	4,338	8,075
Y / Y Net Income Change	2.09 %	11.61 %	-8.87 %	-46.28 %	129.86 %
Return On Equity	14.41 %	15.03 %	15.22 %	19.14 %	43.03 %

Back to REGN Management Effectiveness >> REGN's 5 Years Annual ROE >> Compare REGN ROE to its Competitors

Annual Roe Comment

In 2025 ROE fell to 14.41 %, despite net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
REGN's' Return on Equity at Yahoo Finance
REGN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for REGN's Competitors
Subscribers only: Roe for Regeneron Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for REGN's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %
Chemed Corporation	29.45 %
Solventum Corporation	28.96 %
Pacs Group Inc	27.00 %
Sotera Health Company	26.75 %
Insulet Corporation	26.69 %
Bioventus Inc	25.96 %
Johnson and Johnson	25.74 %
Encompass Health Corporation	25.52 %
Resmed Inc	24.21 %
Healthcare Services Group Inc	24.12 %
Electromed Inc	23.65 %
Iradimed Corporation	23.45 %
Vertex Pharmaceuticals Inc	23.31 %
Lantheus Holdings Inc	23.27 %
Msa Safety Inc	23.15 %
Prestige Consumer Healthcare Inc	21.77 %
Jazz Pharmaceuticals Plc	21.37 %
Neurocrine Biosciences Inc	21.13 %
Universal Health Services Inc	20.89 %

Date modified: 2026-09-15T07:24:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.